LVP Management Team

James Ahern
James AhernFounder, Laidlaw Venture Partners

Jim brings over 15 years’ experience to the Laidlaw Ventures team. His experience is directly relevant in capital formation, venture capital, investment banking and equity capital markets.

Jim has spearheaded relationships with innovation laboratories at universities that has allowed for the incubation of multiple companies in the LVP Portfolio. He has also worked with multiple entrepreneurs as a funding and advisory partner to move therapeutics, medical technologies, and other assets forward.

Jim has acted as a partner to a multitude of successful companies in the private setting, raising capital for emerging growth companies, assisting in expanding their networks, and ultimately providing a public pathway.

In Jim’s capital market experience, at Laidlaw he is credited with establishing a highly recognized quality fundamental health care brand. With a devotion to brand cognizance, Laidlaw Capital Markets is today recognized as a fundamental health care investment bank providing targeted outreach to relevant health care centric investors.

As Head of Capital Markets at Laidlaw, Jim has led or been played an integral role in providing its clients with over 6 Billion dollars in capital. Laidlaw is proud to have acted as sole placement agent on transactions of up to 100 million in transactional value, and alongside some of the most high quality health care centric banks on transactions above and beyond.

Jim currently serves on the board of directors of Algorithm Sciences, Voltron Therapeutics, and PD Theranostics. In addition, proudly serves on the board of overseers of the Massachusetts bay big brothers big sisters foundation. Jim is Vice Chair of the annual BBBS golf outing, an event which brings in approximately 1 million dollars annually for the foundation. He’s also a proud supporter of his alma mater, The Northfield Mount Hermon School, where is serves as Chairmen of the Basketball Academic Center of Excellence.

Patrick Gallagher
Patrick GallagherManaging Partner, Laidlaw Venture Partners

Patrick Gallagher has 20 years of healthcare experience on Wall Street including alternative investments, research and marketing in both the public and private markets. He co-founded Black Diamond Research, LLC (“BDR”), an independent sell-side research firm specializing in healthcare investing, financing and operations, serving the institutional investing community at large. Patrick was Chief Executive Officer of BDR until 2010 and oversaw institutional research and sales. Prior to 2001, he held various sales positions at Kidder Peabody, PaineWebber and New Vernon Associates.

Patrick served as VP of Business Development and Investor Relations as well as a strategic consultant for Kinex Pharmaceuticals, a biotechnology firm focused on next-generation therapies in oncology and immunology. He also has served as an advisor to CHD Biosciences, a novel antimicrobial company. Mr. Gallagher serves on the board of directors of BioSig Technologies, Inc, a medical device company that is developing a proprietary technology platform in the electrophysiology space.

Mr. Gallagher received his BS from the University of Vermont, his MBA from Pennsylvania State University and is a CFA charter holder.

Matt Duffy
Matt DuffyManaging Partner, Laidlaw Venture Partners

Matthew Duffy has more than thirty years’ experience in the healthcare arena, as both a Healthcare and Wall Street executive.

Matt is Managing Partner of Laidlaw Venture Partners and Managing Director of Laidlaw and Company.

Matt has extensive development-to-market experience, beginning at Pfizer, Inc. in Sales, Sales Management and Marketing (CNS, Cardiovasculars, Anti-Infectives, Metabolics). He subsequently led the efforts to bring several important new drugs to commercialization including Synagis (MedImmune, Inc., >$1BB) as head of Marketing and Cinryze (Lev Pharmaceuticals, Inc., >$600MM) as head of Commercial Operations (Sales, Sales Management, Marketing, Managed Care, Patient Services, Distribution, FDA Advisory Committee preparation). Matt was also a Founder and is currently the CEO of Algorithm Sciences, Inc., a late-stage drug/device company focused on pulmonary health.

Previously Matt was President, Chief Operating Officer and a member of the Board of Directors of AltMed Enterprises, LLC, where he was instrumental in raising over $35 million and subsequently facilitated a $7 million private stock sale; executed an overhaul of the company’s Arizona operation which led to a significant improvement in productivity; launched the company’s first retail, which more than doubled revenues; oversaw the commercial launch of AltMed Florida; restructured the corporate operation and implemented a comprehensive budgeting process.

Additionally, Matt has more than 15 years’ experience as an investment banker, buy-side and sell-side equity research analyst and Investor Relations professional. Matt was Managing Director at Roberts Mitani, LLC, a global, healthcare focused investment bank, and then at LifeSci Partners, LLC (global Investment Banking and Investor Relations) where he focused on strategic transactions, financings and investor relations. Previously, Matt co-founded Black Diamond Research, LLC, a sell-side equity research firm specializing in healthcare/biotechnology. Additionally, he served as a healthcare advisor to the Capital M Group, a multi-strategy investment firm.

Matt is Chairman of First Mountain Farms, LLC, a business accelerator. He also served on the Board of Directors of CorMedix, Inc., a publicly traded healthcare company focused on development and launch of products in the Cardio-Renal field as well as Alternative Medical Enterprises, LLC. He also served as a Member of the Board of Trustees and Treasurer of an Independent School in Connecticut.

Matt received his undergraduate degree in Economics from Duke University. He holds Series 7, 63 and 65 securities licenses.